Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Systemic steroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but ∼50% of patients become steroid-refractory or dependent (SR/D). Ruxolitinib is the only Food and Drug Administration– and European Medicines Agency–approved therapy for patients with SR/D aGVHD....

Descripción completa

Detalles Bibliográficos
Autores principales: Socié, Gerard, Niederwieser, Dietger, von Bubnoff, Nikolas, Mohty, Mohamad, Szer, Jeff, Or, Reuven, Garrett, James, Prahallad, Anirudh, Wilke, Celine, Zeiser, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646803/
https://www.ncbi.nlm.nih.gov/pubmed/36827620
http://dx.doi.org/10.1182/blood.2022018579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646803/
https://www.ncbi.nlm.nih.gov/pubmed/36827620
http://dx.doi.org/10.1182/blood.2022018579

Ejemplares similares